631
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How can we refine the prognostic stratification of triple-negative breast cancer?

& ORCID Icon
Pages 1045-1047 | Received 24 Jul 2023, Accepted 10 Aug 2023, Published online: 17 Aug 2023
 

Declaration of interest

F.M. reports personal fees from Roche, Novartis, Gilead, Seagen, and Pfizer, outside the submitted work. M.V.D. reports personal fees from Eli Lilly, Pfizer, Novartis, Roche, Astrazeneca, Merck Sharp & Dohme, BMS, Daiichi-Sankyo, Gilead, Exact Sciences, and Seagen, outside the submitted work.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers of this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper received fundings from Associazione italiana per la Ricerca sul Cancro (IG27152; 5x1000 ID22759).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.